Business intelligence
from24/7 Wall St.
3 months agoThis Growth Stock Surged 63% in 2024. Here's Why 2025 Could Bring An Even Bigger Gain.
Eli Lilly stock has gained 63% in 2024, primarily due to the success of its Mounjaro weight-loss drug.
"We have reduced our full-year outlook due to lower-than-planned branded GLP-1 penetration, which is impacted by the rapid expansion of compounding in the US," said Lars Fruergaard Jorgensen, Novo Nordisk CEO.
"My argument to Mehmet Oz is that if you want to protect Medicare costs in 10 years, have [the Affordable Care Act] and Medicare plans list these drugs now," Ricks said to Bloomberg. "We know so much about how much cost savings there will be downstream in heart disease and other conditions." This statement emphasizes the potential long-term benefits of covering GLP-1 drugs for managing obesity, highlighting a proactive approach to healthcare costs.